Biotech Products, Services & Research focuses on a lifestyle of health and wellness. We are a vertically integrated company, which offers product development, product sales, and integrative cellular therapies. We promote patient referral and management services, which include: nutrition, innovative regenerative medicaltechniques, research and development of a wide range of products.

The Company believes that the Company's new proposed name "Biotech Products Services and Research, Inc." more accurately reflects the current change in focus of the business direction of the Company. Albert Mitrani, the Company's sole officer and a director, intends to engage in the patient referral/medical tourism business.

On July 9, 2015, the Board of Directors approved the implementation of a stock dividend payment in the form of a 1:18 forward stock split whereby shares of Common Stock held by each stockholder of record on the record date of the stock dividend will automatically receive shares at the rate of 1 for 17, without any action on the part of the stockholders. Given that the Company is authorized to issue 90,000,000 shares of common stock, there is no need to increase the authorized share capital of the Company. In connection therewith, Mr. Mitrani agreed to cancel 3,340,000 shares of his common stock.

Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information here.